Setmelanotide
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway
Rhythm · Phase 2 · Completed · Enrollment 164
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Stage 1: Setmelanotide (Open-Label) | n/r | n/r | n/r | n/r |
| Stage 2: Setmelanotide (Double-Blind) | n/r | n/r | n/r | n/r |
| Stage 2: Placebo (Double-Blind) | n/r | n/r | n/r | n/r |
Not shown
- Stage 1: Setmelanotide (Open-Label): endpoint not reported
- Stage 2: Setmelanotide (Double-Blind): endpoint not reported
- Stage 2: Placebo (Double-Blind): endpoint not reported